Advertisement

International Journal of Clinical Oncology

, Volume 23, Issue 1, pp 151–157 | Cite as

Significance of multiple preoperative laboratory abnormalities as prognostic indicators in patients with urothelial carcinoma of the upper urinary tract following radical nephroureterectomy

  • Masatomo Nishikawa
  • Hideaki Miyake
  • Toshifumi Kurahashi
  • Masato Fujisawa
Original Article
  • 135 Downloads

Abstract

Background

The aim of this study was to investigate the prognostic significance of multiple preoperative laboratory abnormalities in upper urinary tract urothelial carcinoma (UUTUC) patients.

Methods

This study included a total of 135 consecutive patients with clinically localized UUTUC who underwent radical nephroureterectomy (RNU). The impact of several preoperative blood-based markers in addition to conventional clinical factors on extravesical recurrence-free survival (eRFS) in these patients was retrospectively evaluated.

Results

Despite the lack of a significant correlation between conventional clinical factors and any of the postoperative pathologic parameters, preoperative laboratory abnormalities were shown to have a significant impact on some pathological factors reflecting an aggressive phenotype as follows—C-reactive protein (CRP) level on pathological stage, De Ritis (aspartate transaminase/alanine transaminase) ratio on nodal involvement, and neutrophil−lymphocyte ratio (NLR) on pathological stage. During the observation period of this study (median 36.1 months), extravesical disease recurrence was detected in 44 (32.6%) of the 135 patients with a 5-year eRFS rate of 62.1%. Of several factors examined, the CRP level, De Ritis ratio, and NRL were significantly correlated with eRFS on univariate analysis. Of these significant factors, the De Ritis ratio and NRL were identified as independent predictors of eRFS on multivariate analysis. Moreover, there were significant differences in eRFS according to the positive numbers of these two independent risk factors.

Conclusions

These findings suggest that it is important to consider laboratory abnormalities, particularly the De Ritis ratio and NLR, to predict disease recurrence following RNU in patients with clinically localized UUTUC.

Keywords

Upper urinary tract urothelial carcinoma Radical nephroureterectomy Prognosis Laboratory abnormalities 

Notes

Compliance with ethical standards

Conflict of interest

We declare that we have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Raman JD, Messer J, Sielatycki JA et al (2011) Incidence and survival of patients with carcinoma of the ureter and renal pelvis in the USA, 1973–2005. BJU Int 107:1059–1064CrossRefPubMedGoogle Scholar
  2. 2.
    Margulis V, Shariat SF, Matin SF et al (2009) Outcomes of radical nephroureterectomy: a series from the upper tract urothelial carcinoma collaboration. Cancer 115:1224–1233CrossRefPubMedGoogle Scholar
  3. 3.
    Rink M, Ehdaie B, Cha EK et al (2012) Stage-specific impact of tumor location on oncologic outcomes in patients with upper and lower tract urothelial carcinoma following radical surgery. Eur Urol 62:677–684CrossRefPubMedGoogle Scholar
  4. 4.
    Roscigno M, Brausi M, Heidenreich A et al (2011) Lymphadenectomy at the time of nephroureterectomy for upper tract urothelial cancer. Eur Urol 60:776–783CrossRefPubMedGoogle Scholar
  5. 5.
    Matin SF, Margulis V, Kamat A et al (2010) Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high-risk upper tract transitional cell carcinoma. Cancer 116:3127–3134CrossRefPubMedGoogle Scholar
  6. 6.
    Lughezzani G, Burger M, Margulis V et al (2012) Prognostic factors in upper urinary tract urothelial carcinomas: a comprehensive review of the current literature. Eur Urol 62:100–114CrossRefPubMedGoogle Scholar
  7. 7.
    Scolieri MJ, Paik ML, Brown SL et al (2000) Limitations of computed tomography in the preoperative staging of upper tract urothelial carcinoma. Urology 56:930–934CrossRefPubMedGoogle Scholar
  8. 8.
    Yoshida S, Koga F, Masuda H et al (2014) Role of diffusion-weighted magnetic resonance imaging as an imaging biomarker of urothelial carcinoma. Int J Urol 21:1190–1200CrossRefPubMedGoogle Scholar
  9. 9.
    Ku JH, Kim M, Choi WS et al (2014) Preoperative serum albumin as a prognostic factor in patients with upper urinary tract urothelial carcinoma. Int Braz J Urol 40:753–762CrossRefPubMedGoogle Scholar
  10. 10.
    Rink M, Sharifi N, Fritsche HM et al (2014) Impact of preoperative anemia on oncologic outcomes of upper tract urothelial carcinoma treated with radical nephroureterectomy. J Urol 191:316–322CrossRefPubMedGoogle Scholar
  11. 11.
    Saito K, Kawakami S, Ohtsuka Y et al (2007) The impact of preoperative serum C-reactive protein on the prognosis of patients with upperurinary tract urothelial carcinoma treated surgically. BJU Int 100:269–273CrossRefPubMedGoogle Scholar
  12. 12.
    Nishikawa M, Miyake H, Fujisawa M (2016) De Ritis (aspartate transaminase/alanine transaminase) ratio as a significant predictor of recurrence-free survival in patients with upper urinary tract urothelial carcinoma following nephroureterectomy. Urol Oncol 34:417.e9–417.e15CrossRefGoogle Scholar
  13. 13.
    Morizane S, Yumioka T, Yamaguchi N et al (2015) Risk stratification model, including preoperative serum C-reactive protein and estimated glomerular filtration rate levels, in patients with upper urinary tract urothelial carcinoma undergoing radical nephroureterectomy. Int Urol Nephrol 47:1335–1341CrossRefPubMedGoogle Scholar
  14. 14.
    Zhang XK, Zhang ZL, Lu X et al (2016) Prognostic significance of preoperative serum lactate dehydrogenase in upper urinary tracturothelial carcinoma. Clin Genitourin Cancer 14(341–345):e3Google Scholar
  15. 15.
    Dalpiaz O, Ehrlich GC, Mannweiler S et al (2014) Validation of pretreatment neutrophil-lymphocyte ratio as a prognostic factor in a European cohort of patients with upper tract urothelial carcinoma. BJU Int 114:334–339PubMedGoogle Scholar
  16. 16.
    Fujita K, Tanigawa G, Imamura R et al (2013) Preoperative serum sodium is associated with cancer-specific survival in patients with upper urinary tract urothelial carcinoma treated bynephroureterectomy. Int J Urol 20:594–601CrossRefPubMedGoogle Scholar
  17. 17.
    Pichler M, Dalpiaz O, Ehrlich GC et al (2014) Validation of the preoperative plasma fibrinogen level as a prognostic factor in a European cohort of patients with localized upper tract urothelial carcinoma. J Urol 191:920–925CrossRefPubMedGoogle Scholar
  18. 18.
    Terakawa T, Miyake H, Hara I et al (2008) Retroperitoneoscopic nephroureterectomy for upper urinary tract cancer: a comparative study with conventional open retroperitoneal nephroureterectomy. J Endourol 22:1693–1699CrossRefPubMedGoogle Scholar
  19. 19.
    Rouprêt M, Babjuk M, Compérat E et al (2015) European association of urology guidelines on upper urinary tract urothelial cell carcinoma: 2015 update. Eur Urol 68:868–879CrossRefPubMedGoogle Scholar
  20. 20.
    NCCN guidelines. Clinical guidelines in oncology. Bladder cancer, version 2.2012. National Comprehensive Cancer NetworkWeb site. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed 12 Jan 2016
  21. 21.
    Scholl SM, Pallud C, Beuvon F et al (1994) Anti-colony-stimulating factor-1 antibody staining in primary breast adenocarcinomas correlates with marked inflammatory cell infiltrates and prognosis. J Natl Cancer Inst 86:120–126CrossRefPubMedGoogle Scholar
  22. 22.
    Sheu BC, Hsu SM, Ho HN et al (1999) Reversed CD4/CD8 ratios of tumor-infiltrating lymphocytes are correlated with the progression of human cervical carcinoma. Cancer 86:1537–1543CrossRefPubMedGoogle Scholar

Copyright information

© Japan Society of Clinical Oncology 2017

Authors and Affiliations

  • Masatomo Nishikawa
    • 1
    • 2
  • Hideaki Miyake
    • 2
    • 3
  • Toshifumi Kurahashi
    • 1
  • Masato Fujisawa
    • 2
  1. 1.Department of UrologySeirei Mikatabara HospitalHamamatsuJapan
  2. 2.Division of UrologyKobe University Graduate School of MedicineKobeJapan
  3. 3.Department of UrologyHamamatsu University School of MedicineHamamatsuJapan

Personalised recommendations